Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q96LL9

UPID:
DJC30_HUMAN

ALTERNATIVE NAMES:
Williams-Beuren syndrome chromosomal region 18 protein

ALTERNATIVE UPACC:
Q96LL9; Q9BSG8

BACKGROUND:
The mitochondrial protein, DnaJ homolog subfamily C member 30, mitochondrial, is crucial for neuronal mitochondrial respiration. It is involved in ATP synthesis by associating with the ATP synthase complex and may act as a chaperone for the turnover of damaged mitochondrial complex I N-module subunits. This process is essential for maintaining complex I functional efficiency and protecting against oxidative stress.

THERAPEUTIC SIGNIFICANCE:
Linked to a rare autosomal recessive form of Leber hereditary optic neuropathy, DnaJ homolog subfamily C member 30, mitochondrial's involvement in this mitochondrial disease underscores the therapeutic potential of understanding its function. Exploring its role could lead to innovative treatments for vision loss associated with this condition.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.